Navigation Links
ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases Entrepreneurial Company Award 2009
Date:10/19/2009

Appenzell, Switzerland, October 19, 2009 / b3c newswire / - ERGONEX Pharma received one of the prestigious European Orphan Diseases Entrepreneurial Company Award on the occasion of Frost & Sullivan's '2009 Excellence in Healthcare Awards Banquet,' held in London on 8th October 2009. The highly competitive award was presented to ERGONEX Pharma in recognition of the company's innovative therapeutic concept, its impressive display of technological know-how and targeted vision.

ERGONEX Pharma is focused on the clinical development and commercialisation of Terguride for the treatment of distinct orphan diseases. Terguride is currently being evaluated for the treatment of pulmonary arterial hypertension (PAH) in a Phase II trial in Europe and headline results are expected in 2010.

Dr. Rudolf Reiter, CEO of ERGONEX Pharma comments: "This award comes at an exciting and challenging time for ERGONEX Pharma. I see it as recognition of the vision, the commitment and work of the company, which would not have been possible without the continued support, expertise and out-of-the-box thinking of our partners in the on-going clinical trial. We believe that Terguride has the potential to contribute a new quality to emerging combination therapies for patients, who do not tolerate, have become resistant to or are insufficiently controlled by current treatment options in PAH.

The Frost & Sullivan Healthcare Awards Banquet honours Europe's best healthcare companies for their achievements over the course of this year. Frost & Sullivan's highly competitive awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.

About Pulmona
'/>"/>

b3c newswire

Page: 1 2

Related biology news :

1. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
2. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
3. Science survey ranks top biopharma employers
4. Jean-Pol Tassin wins the 2009 ECNP Neuropsychopharmacological Award
5. Researchers prolong the half-life of biopharmaceutical proteins
6. UA pharmacy research shows prescribers miss potentially dangerous drug pairs
7. 22nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey
8. 22nd Congress of the European College of Neuropsychopharmacology
9. Simulating pharmaceutical and personal care product transport
10. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
11. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2014)... analysis growing in importance for both basic researchers ... and the University of Maryland have developed a ... of gene activity from RNA sequencing (RNA-seq) data., ... famously speedy fish, estimates of gene expression that ... a few minutes, with accuracy that equals or ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
(Date:4/18/2014)... techniques like X-ray crystallography and nuclear magnetic resonance imaging ... of molecules, but such efforts have long been hampered ... a specific molecule and often in ordered and crystalized ... impossible to peer into the structure of most molecules. ... be a thing of the past. , A ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3MRI, on a molecular scale 2MRI, on a molecular scale 3
... voices, but now helium is also helping people with ... the University of Alberta in Edmonton, Canada have discovered ... allowed patients with chronic obstructive pulmonary disease (COPD) to ... per cent. COPD is a disease of the lungs ...
... For the first time in humans, scientists have found ... injuries caused by repetitive motion. , Their findings ... debilitating conditions such as carpal tunnel syndrome and tendonitis. ... researchers Ann Barr and Mary Barbe and their doctoral ...
... Two researchers from the University Hospital and the Center ... Navarra have published an article in Nature Cancer ... the area of cancer studies. The article, written by ... from the United States and Great Britain, addresses the ...
Cached Biology News:Helium helps patients breathe easier 2Red flag for repetitive stress injuries identified for first time in humans 2Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies 2
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that ... investment conferences. , Vincent Milano, president and chief ... 20th Annual Healthcare Conference at 4:30 P.M. EST on ... held at the Waldorf=Astoria in New York City. , ...
... 50/50 joint venture agreement signed with Hunan, Biopharmaceutical ... manufacturing facility, - Biologics: 23% growth in sales and to ... of KINLYTIC(TM) thrombolytic, agent for pulmonary embolism, ... under, agreement, - Dr. Mark ...
... DNDN ) today announced that management will present at the following upcoming ... New York City, Tuesday, November 10, 2009, ... Phoenix, Arizona, Friday, November 13, 2009, ... Conference, New York City, Tuesday, November 17, ...
Cached Biology Technology:ViroPharma to Present at Three November Healthcare Conferences 2Microbix Biosystems Provides a Corporate Update 2Microbix Biosystems Provides a Corporate Update 3Microbix Biosystems Provides a Corporate Update 4Microbix Biosystems Provides a Corporate Update 5Microbix Biosystems Provides a Corporate Update 6Microbix Biosystems Provides a Corporate Update 7